{"id":"https://openalex.org/W3032348824","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.1056","title":"The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2- negative (HER2-) metastatic breast cancer (MBC).","display_name":"The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2- negative (HER2-) metastatic breast cancer (MBC).","publication_year":2020,"publication_date":"2020-05-20","ids":{"openalex":"https://openalex.org/W3032348824","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.1056","mag":"3032348824"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2020.38.15_suppl.1056","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.1056","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.1056","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5088164483","display_name":"Sudpreeda Chainitikun","orcid":"https://orcid.org/0000-0002-7738-9945","observed_orcids":["https://orcid.org/0000-0002-7738-9945"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sudpreeda Chainitikun","raw_affiliation_strings":["Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069261710","display_name":"James Patrick Long","orcid":"https://orcid.org/0000-0001-5853-5938","observed_orcids":["https://orcid.org/0000-0001-5853-5938"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James Long","raw_affiliation_strings":["Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082393711","display_name":"Rub\u00e9n Rodr\u00edguez\u2010Bautista","orcid":"https://orcid.org/0009-0009-2766-8629","observed_orcids":["https://orcid.org/0009-0009-2766-8629"]},"institutions":[{"id":"https://openalex.org/I4210153971","display_name":"Instituto Nacional de Cancerolog\u00eda","ror":"https://ror.org/04z3afh10","country_code":"MX","type":"government","lineage":["https://openalex.org/I4210095685","https://openalex.org/I4210153971"]}],"countries":["MX"],"is_corresponding":false,"raw_author_name":"Ruben Rodriguez-Bautista","raw_affiliation_strings":["National Cancer Institute, Mexico City, Mexico;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Cancer Institute, Mexico City, Mexico;","institution_ids":["https://openalex.org/I4210153971"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018426062","display_name":"Toshiaki Iwase","orcid":"https://orcid.org/0000-0002-5302-2292","observed_orcids":["https://orcid.org/0000-0002-5302-2292"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Toshiaki Iwase","raw_affiliation_strings":["Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110083321","display_name":"Debu Tripathy","orcid":"https://orcid.org/0000-0002-5711-2404","observed_orcids":["https://orcid.org/0000-0002-5711-2404"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Debu Tripathy","raw_affiliation_strings":["Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112215616","display_name":"Takeo Fujii","orcid":"https://orcid.org/0000-0003-3747-2688","observed_orcids":["https://orcid.org/0000-0003-3747-2688"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Takeo Fujii","raw_affiliation_strings":["Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5088814426","display_name":"Naoto Tada Ueno","orcid":"https://orcid.org/0000-0002-0166-7275","observed_orcids":["https://orcid.org/0000-0002-0166-7275"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Naoto T. Ueno","raw_affiliation_strings":["Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"38","issue":"15_suppl","first_page":"1056","last_page":"1056"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9667999744415283,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9667999744415283,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.029200000688433647,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.0024999999441206455,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/endocrine-resistant-breast-cancer","display_name":"endocrine-resistant breast cancer","score":0.7670000195503235},{"id":"https://openalex.org/keywords/hormone-receptor-positive-her2-negative-metastatic-breast-cancer","display_name":"hormone receptor-positive HER2-negative metastatic breast cancer","score":0.8790000081062317},{"id":"https://openalex.org/keywords/first-line-chemotherapy","display_name":"first-line chemotherapy","score":0.9819999933242798},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.8450000286102295},{"id":"https://openalex.org/keywords/mtor-inhibitors","display_name":"mTOR inhibitors","score":0.9700000286102295},{"id":"https://openalex.org/keywords/capecitabine","display_name":"capecitabine","score":0.8479999899864197},{"id":"https://openalex.org/keywords/taxanes","display_name":"taxanes","score":0.9900000095367432},{"id":"https://openalex.org/keywords/time-to-treatment-failure","display_name":"time to treatment failure","score":0.7900000214576721},{"id":"https://openalex.org/keywords/predictive-factors","display_name":"predictive factors","score":0.7639999985694885},{"id":"https://openalex.org/keywords/inflammatory-breast-cancer","display_name":"inflammatory breast cancer","score":0.9179999828338623},{"id":"https://openalex.org/keywords/treatment-sequencing","display_name":"treatment sequencing","score":0.35600000619888306}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8485188484191895},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7085293531417847},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.707568883895874},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.6356779336929321},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.5937406420707703},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.5888547301292419},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.5046530961990356},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.48388704657554626},{"id":"https://openalex.org/C2776215463","wikidata":"https://www.wikidata.org/wiki/Q419143","display_name":"Anastrozole","level":5,"score":0.4625095725059509},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.44200676679611206},{"id":"https://openalex.org/C2777909004","wikidata":"https://www.wikidata.org/wiki/Q420207","display_name":"Capecitabine","level":4,"score":0.43561357259750366},{"id":"https://openalex.org/C2777176818","wikidata":"https://www.wikidata.org/wiki/Q412178","display_name":"Tamoxifen","level":4,"score":0.2328488826751709},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.09566661715507507},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.08930355310440063}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2020.38.15_suppl.1056","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.1056","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.1056","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3046002699","https://openalex.org/W4397007235","https://openalex.org/W4379285610","https://openalex.org/W4367174989","https://openalex.org/W3206548539","https://openalex.org/W2994696359","https://openalex.org/W3006217746","https://openalex.org/W7129583955","https://openalex.org/W2796824128","https://openalex.org/W4402271901"],"abstract_inverted_index":{"1056":[0],"Background:":[1],"Combinations":[2],"of":[3,16,33,63,75,116,236,258,319],"endocrine":[4],"therapy":[5,9,91],"(ET)":[6],"and":[7,46,59,103,124,179,191,208],"targeted":[8,90,169],"(CDK4/6":[10],"or":[11,88,195],"mTOR":[12,177],"inhibitors)":[13],"are":[14,39],"standard":[15],"care":[17],"for":[18,119,200,284,316],"HR+/HER2-":[19,78],"MBC.":[20,68,120],"When":[21],"ET":[22,48,86,237],"is":[23,27],"not":[24,300],"effective,":[25],"chemotherapy":[26,34,64,82,118,186,233],"commonly":[28],"used.":[29],"However,":[30],"clinical":[31],"outcomes":[32],"in":[35,66,203,266,288,296],"the":[36,60,128,142,146,228,281,317,323],"endocrine-resistant":[37,67,327],"setting":[38,268],"limited.":[40],"We":[41,53,70,99,121],"hypothesized":[42],"that":[43],"clinicopathological":[44,102],"baseline":[45,101],"prior":[47,209,262,292],"factors":[49,58,202],"determine":[50],"chemotherapy\u2019s":[51],"efficacy.":[52],"sought":[54],"to":[55,112,137,211,264,308],"identify":[56],"predictive":[57,314],"compare":[61],"efficacies":[62],"agents":[65,187],"Methods:":[69],"conducted":[71],"a":[72,204,212,224,312],"retrospective":[73],"study":[74],"patients":[76,144,155,165,260,289],"with":[77,87,172,176,181,218,223],"MBC":[79],"who":[80,290,298],"received":[81,167,291],"after":[83],"progression":[84],"on":[85,232],"without":[89],"at":[92],"MD":[93],"Anderson":[94],"Cancer":[95],"Center":[96],"from":[97],"1999-2017.":[98],"collected":[100],"all":[104,201],"treatment":[105,113,222],"data.":[106],"The":[107,183],"primary":[108],"endpoint":[109],"was":[110,149,286],"time":[111],"failure":[114],"(TTF)":[115],"first-line":[117],"performed":[122],"univariate":[123],"multivariate":[125,205],"analyses":[126],"using":[127],"Cox":[129],"proportional":[130],"hazard":[131,240],"model.":[132],"Kaplan-Meier":[133],"methods":[134],"were":[135,188,215],"used":[136],"analyze":[138],"TTF.":[139,220],"Results:":[140],"In":[141],"1,258":[143],"analyzed,":[145],"mean":[147],"age":[148],"55.3":[150],"years":[151],"(range":[152],"21-91).":[153],"Forty-five":[154],"(3.6%)":[156],"had":[157,227,250,261,311,322],"inflammatory":[158],"breast":[159,328],"cancer":[160],"(IBC).":[161],"Three":[162],"hundred":[163],"ninety":[164],"(31%)":[166],"previous":[168],"therapy:":[170],"264":[171],"CDK4/6":[173,213,225,309],"inhibitor,":[174,178],"205":[175],"79":[180],"both.":[182],"most":[184],"frequent":[185],"capecitabine":[189],"(48.9%)":[190],"taxanes":[192,256,265,285,294],"(paclitaxel,":[193],"nab-paclitaxel,":[194],"docetaxel;":[196],"28.6%).":[197],"After":[198],"adjustment":[199],"model,":[206],"IBC":[207],"exposure":[210,263,307],"inhibitor":[214,226,310],"significantly":[216,251],"associated":[217],"shorter":[219,287],"Previous":[221,306],"strongest":[229],"negative":[230,313],"effect":[231,315],"TTF":[234,254,283],"regardless":[235,257],"duration":[238],"(adjusted":[239],"ratio":[241],"[HR]":[242],"1.84;":[243],"95%CI":[244,275],"1.49-2.27;":[245],"p":[246,277],"<":[247,278],"0.001).":[248,279],"Capecitabine":[249,321],"longer":[252],"median":[253,282],"than":[255,295],"whether":[259],"(neo)adjuvant":[267,293],"(6.1":[269],"vs":[270,302],"4.9":[271],"months;":[272],"HR":[273],"0.64;":[274],"0.55-0.75;":[276],"Conversely,":[280],"those":[297],"did":[299],"(4.5":[301],"5.1":[303],"months).":[304],"Conclusions:":[305],"efficacy":[318,325],"chemotherapy.":[320],"best":[324],"against":[326],"cancer.":[329]},"counts_by_year":[{"year":2021,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2020-06-05T00:00:00"}